The estimated Net Worth of Richard Scranton is at least 896 千$ dollars as of 8 November 2019. Richard Scranton owns over 19,448 units of Pacira BioSciences Inc stock worth over 461,617$ and over the last 7 years Richard sold PCRX stock worth over 434,762$.
Richard has made over 4 trades of the Pacira BioSciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Richard exercised 19,448 units of PCRX stock worth 279,468$ on 8 November 2019.
The largest trade Richard's ever made was exercising 19,448 units of Pacira BioSciences Inc stock on 8 November 2019 worth over 279,468$. On average, Richard trades about 6,481 units every 75 days since 2017. As of 8 November 2019 Richard still owns at least 35,509 units of Pacira BioSciences Inc stock.
You can see the complete history of Richard Scranton stock trades at the bottom of the page.
Richard's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY, NJ, 07054.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over 321,391,130$ worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth 15,133,188$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Carl L Gordon、Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of 491,036$. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth 20,034$.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: